ES2928586T3 - Fenilacetato de L-ornitina y métodos para elaborar el mismo - Google Patents

Fenilacetato de L-ornitina y métodos para elaborar el mismo Download PDF

Info

Publication number
ES2928586T3
ES2928586T3 ES20161306T ES20161306T ES2928586T3 ES 2928586 T3 ES2928586 T3 ES 2928586T3 ES 20161306 T ES20161306 T ES 20161306T ES 20161306 T ES20161306 T ES 20161306T ES 2928586 T3 ES2928586 T3 ES 2928586T3
Authority
ES
Spain
Prior art keywords
ornithine
phenyl acetate
composition
approximately
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20161306T
Other languages
English (en)
Spanish (es)
Inventor
Keith Anderson
Jim Behling
Christine Henderson Dougan
Stephen William Watt
Peter Manini
Attilia Figini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocera Therapeutics Inc
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Application granted granted Critical
Publication of ES2928586T3 publication Critical patent/ES2928586T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES20161306T 2009-04-03 2010-04-01 Fenilacetato de L-ornitina y métodos para elaborar el mismo Active ES2928586T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16667609P 2009-04-03 2009-04-03

Publications (1)

Publication Number Publication Date
ES2928586T3 true ES2928586T3 (es) 2022-11-21

Family

ID=42828717

Family Applications (3)

Application Number Title Priority Date Filing Date
ES17185173T Active ES2791524T3 (es) 2009-04-03 2010-04-01 Fenilacetato de L-ornitina y métodos de elaboración del mismo
ES20161306T Active ES2928586T3 (es) 2009-04-03 2010-04-01 Fenilacetato de L-ornitina y métodos para elaborar el mismo
ES10759442.6T Active ES2652187T3 (es) 2009-04-03 2010-04-01 Fenilacetato de l-ornitina y métodos para elaborar el mismo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES17185173T Active ES2791524T3 (es) 2009-04-03 2010-04-01 Fenilacetato de L-ornitina y métodos de elaboración del mismo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10759442.6T Active ES2652187T3 (es) 2009-04-03 2010-04-01 Fenilacetato de l-ornitina y métodos para elaborar el mismo

Country Status (26)

Country Link
US (9) US8173706B2 (enExample)
EP (4) EP3686183B1 (enExample)
JP (6) JP6144488B2 (enExample)
KR (6) KR102123243B1 (enExample)
CN (3) CN106810464B (enExample)
AU (1) AU2010232521B2 (enExample)
BR (1) BRPI1013657A2 (enExample)
CA (5) CA3077846C (enExample)
CY (1) CY1119843T1 (enExample)
DK (3) DK2413924T3 (enExample)
EA (2) EA023051B1 (enExample)
ES (3) ES2791524T3 (enExample)
HR (2) HRP20221232T8 (enExample)
HU (2) HUE060371T2 (enExample)
IL (2) IL215449B (enExample)
LT (2) LT3686183T (enExample)
MX (4) MX356608B (enExample)
NO (1) NO2413924T3 (enExample)
NZ (3) NZ619235A (enExample)
PL (2) PL2413924T3 (enExample)
PT (2) PT2413924T (enExample)
SG (3) SG10201406300YA (enExample)
SI (1) SI2413924T1 (enExample)
SM (2) SMT202200395T1 (enExample)
WO (1) WO2010115055A1 (enExample)
ZA (1) ZA201107189B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341120T3 (es) 2004-11-26 2010-06-15 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatia hepatica.
EA023051B1 (ru) 2009-04-03 2016-04-29 Осера Терапьютикс, Инк. Кристаллические формы фенилацетата l-орнитина и их применение
EA025735B1 (ru) 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
US8068011B1 (en) 2010-08-27 2011-11-29 Q Street, LLC System and method for interactive user-directed interfacing between handheld devices and RFID media
ES2720148T3 (es) 2010-10-06 2019-07-18 Ocera Therapeutics Inc Métodos de fabricación de fenilacetato de L-ornitina
CN102993037B (zh) * 2012-11-20 2015-03-04 南京工业大学 一种l-鸟氨酸苯乙酸盐的制备方法
CN105481725B (zh) * 2014-09-18 2019-01-22 博瑞生物医药（苏州）股份有限公司 L-精氨酸苯乙酸盐的晶型及其制备方法
DK3223829T3 (da) 2014-11-24 2020-02-10 Ucl Business Ltd Behandling af sygdomme associeret med hepatisk stellat-celleaktivering under anvendelse af ammoniak-sænkende terapier
EP3285756B1 (en) 2015-04-20 2023-02-22 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
US20200206174A1 (en) * 2015-09-25 2020-07-02 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
RU2018113801A (ru) * 2015-11-13 2019-12-16 Осера Терапьютикс, Инк. Составы l-орнитин фенилацетата
US11219611B2 (en) * 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP7126520B2 (ja) * 2017-05-11 2022-08-26 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンフェニルアセテートを製造する方法
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
CA3138914A1 (en) 2019-05-09 2020-11-12 Ocera Therapeutics, Inc. Methods of assessing and treating hepatic encephalopathy
CN110707221B (zh) * 2019-09-25 2023-09-01 北京大学深圳研究生院 氨基酸离子液体在制备钙钛矿光电器件中钙钛矿层的应用
CN114786662A (zh) * 2019-10-16 2022-07-22 欧塞拉治疗有限公司 鸟氨酸苯乙酸盐用于治疗高氨血症的剂量和用途
WO2023240081A1 (en) * 2022-06-06 2023-12-14 Yale University Treatment, amelioration, and/or prevention of inflammatory and autoimmune diseases
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (enExample) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4100161A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US3950529A (en) * 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4352814A (en) * 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) * 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
JP2522034B2 (ja) * 1988-12-27 1996-08-07 味の素株式会社 α−ケト酸・アミノ酸塩化合物及びその製造方法
JPH03273578A (ja) 1990-03-23 1991-12-04 Ricoh Co Ltd 対物レンズクリーニング装置
DE4020980C1 (enExample) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5560490A (en) 1992-09-09 1996-10-01 Fisons Plc Pharmaceutical packaging with capsule sealing means
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5840891A (en) * 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
WO1997030167A1 (en) 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) * 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
CA2374273A1 (en) 1999-05-21 2000-11-30 Takeda Chemical Industries, Ltd. Liver function controlling agents
US6768024B1 (en) * 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
DE60233558D1 (de) 2001-03-15 2009-10-15 Takashi Abe Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
US6503530B1 (en) * 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
WO2004019928A1 (ja) 2002-08-30 2004-03-11 Ajinomoto Co., Inc. 肝疾患治療剤
US20050059150A1 (en) * 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) * 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
AU2005216251B2 (en) * 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005108339A2 (en) * 2004-05-06 2005-11-17 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
JP2008511611A (ja) * 2004-08-30 2008-04-17 ルナメツド・インコーポレーテツド 治療用４−フェニル酪酸制御放出製剤
ES2341120T3 (es) 2004-11-26 2010-06-15 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatia hepatica.
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
ME01879B (me) 2005-11-17 2014-12-20 Stabilna formulacija amorfnih perindopril soli, postupak njihove pripreme, posebno industrijske proizvodnje i njihova upotreba u terapiji hipertenzije
EA023051B1 (ru) * 2009-04-03 2016-04-29 Осера Терапьютикс, Инк. Кристаллические формы фенилацетата l-орнитина и их применение
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
EA025735B1 (ru) 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
JP2011236160A (ja) 2010-05-11 2011-11-24 Shinshu Univ 非アルコール性肝疾患治療薬
ES2720148T3 (es) 2010-10-06 2019-07-18 Ocera Therapeutics Inc Métodos de fabricación de fenilacetato de L-ornitina
HK1210699A1 (en) 2012-11-21 2016-05-06 Horizon Therapeutics, Inc. Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
DK3223829T3 (da) 2014-11-24 2020-02-10 Ucl Business Ltd Behandling af sygdomme associeret med hepatisk stellat-celleaktivering under anvendelse af ammoniak-sænkende terapier
EP3285756B1 (en) 2015-04-20 2023-02-22 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE

Also Published As

Publication number Publication date
EP2413924B1 (en) 2017-09-27
DK3263100T3 (da) 2020-05-11
EP3263100A1 (en) 2018-01-03
PT3686183T (pt) 2022-10-03
PL2413924T3 (pl) 2018-02-28
KR102217081B1 (ko) 2021-02-18
US8173706B2 (en) 2012-05-08
EP4101838A1 (en) 2022-12-14
CA3205755A1 (en) 2010-10-07
US8785498B2 (en) 2014-07-22
LT3686183T (lt) 2022-11-10
US20200239406A1 (en) 2020-07-30
EA034409B1 (ru) 2020-02-05
SMT202200395T1 (it) 2022-11-18
IL215449B (en) 2019-01-31
US20220162155A1 (en) 2022-05-26
KR102399540B1 (ko) 2022-05-17
SI2413924T1 (en) 2018-01-31
KR102123243B1 (ko) 2020-06-17
NZ595706A (en) 2014-01-31
EP2413924A4 (en) 2013-01-02
CA2998344A1 (en) 2010-10-07
HRP20171962T1 (hr) 2018-02-09
MX2011010262A (es) 2012-01-25
US20120208885A1 (en) 2012-08-16
JP6010154B2 (ja) 2016-10-19
HUE035921T2 (en) 2018-05-28
JP2022088504A (ja) 2022-06-14
SG10202010988WA (en) 2020-12-30
KR20120006039A (ko) 2012-01-17
CA2998434C (en) 2020-05-12
KR20210019592A (ko) 2021-02-22
LT2413924T (lt) 2018-02-12
JP6328737B2 (ja) 2018-05-23
HUE060371T2 (hu) 2023-02-28
US20140288327A1 (en) 2014-09-25
NO2413924T3 (enExample) 2018-02-24
ES2652187T3 (es) 2018-01-31
JP6647336B2 (ja) 2020-02-14
BRPI1013657A2 (pt) 2016-04-26
DK3686183T3 (da) 2022-10-03
JP2017081940A (ja) 2017-05-18
US20100280119A1 (en) 2010-11-04
EP2413924A1 (en) 2012-02-08
HRP20221232T8 (hr) 2023-02-03
NZ708458A (en) 2017-02-24
EA201171216A1 (ru) 2012-05-30
SG10201406300YA (en) 2015-01-29
ZA201107189B (en) 2012-12-27
ES2791524T3 (es) 2020-11-04
CN104230730A (zh) 2014-12-24
US9034925B2 (en) 2015-05-19
CN106810464B (zh) 2019-01-22
CA2757373C (en) 2018-05-08
CA3077846A1 (en) 2010-10-07
IL263784A (en) 2019-01-31
US11161802B2 (en) 2021-11-02
CN102421432B (zh) 2014-09-17
KR101975726B1 (ko) 2019-05-07
JP2012522803A (ja) 2012-09-27
HK1248558A1 (en) 2018-10-19
EP3686183B1 (en) 2022-08-03
AU2010232521B2 (en) 2015-07-16
MX375111B (es) 2025-03-06
IL215449A0 (en) 2011-12-29
MX388894B (es) 2025-03-20
US10173964B2 (en) 2019-01-08
DK2413924T3 (en) 2017-12-11
US20180044281A1 (en) 2018-02-15
CA2998344C (en) 2020-06-02
US20130296429A1 (en) 2013-11-07
PT2413924T (pt) 2018-01-04
US10550069B2 (en) 2020-02-04
JP6144488B2 (ja) 2017-06-07
NZ619235A (en) 2015-06-26
CN102421432A (zh) 2012-04-18
EA201500650A1 (ru) 2015-10-30
AU2010232521A1 (en) 2011-11-17
US20180319736A1 (en) 2018-11-08
KR101844605B1 (ko) 2018-04-02
WO2010115055A1 (en) 2010-10-07
EP3686183A1 (en) 2020-07-29
MX2020009699A (es) 2021-12-17
CA2757373A1 (en) 2010-10-07
JP2020100624A (ja) 2020-07-02
CY1119843T1 (el) 2018-06-27
US20150251990A1 (en) 2015-09-10
CA2998434A1 (en) 2010-10-07
HRP20221232T1 (hr) 2022-12-23
EP3263100B1 (en) 2020-04-01
CA3077846C (en) 2023-08-22
JP2015145372A (ja) 2015-08-13
JP7086118B2 (ja) 2022-06-17
JP2018138575A (ja) 2018-09-06
CN104230730B (zh) 2017-05-24
KR20180033313A (ko) 2018-04-02
SMT201700601T1 (it) 2018-03-08
EA023051B1 (ru) 2016-04-29
SG174982A1 (en) 2011-11-28
US8492439B2 (en) 2013-07-23
KR20220067001A (ko) 2022-05-24
US9604909B2 (en) 2017-03-28
KR20190068561A (ko) 2019-06-18
MX356608B (es) 2018-06-06
CN106810464A (zh) 2017-06-09
KR20200070438A (ko) 2020-06-17
PL3686183T3 (pl) 2022-11-28

Similar Documents

Publication Publication Date Title
ES2928586T3 (es) Fenilacetato de L-ornitina y métodos para elaborar el mismo
AU2017202081B2 (en) L-ornithine phenyl acetate and methods of making thereof
HK40033714B (en) L-ornithine phenyl acetate and methods of making thereof
HK1248558B (en) L-ornithine phenyl acetate and methods of making thereof
HK1166699A (en) L-ornithine phenyl acetate and methods of making thereof
HK1166699B (en) L-ornithine phenyl acetate and methods of making thereof